Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.988 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; citric acid; sodium citrate; sodium chloride; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.977 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: sodium chloride; sodium citrate; citric acid; water for injections; nitrogen - ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ondansetron (injection) is also indicated for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - dexmedetomidine hydrochloride, quantity: 1182 microgram (equivalent: dexmedetomidine, qty 1000 microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - icu sedation.,for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine ever pharma by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

interpharma pty ltd - dexmedetomidine hydrochloride, quantity: 472.8 microgram (equivalent: dexmedetomidine, qty 400 microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - icu sedation.,for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine ever pharma by continuous infusion in these patients should not exceed 24 hours.,procedural sedation,for sedation of non-intubated patients prior to and/or during surgical and other procedures.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 9.98 mg (equivalent: ondansetron, qty 8 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; sodium chloride; sodium citrate dihydrate; citric acid monohydrate - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - ondansetron hydrochloride dihydrate, quantity: 4.99 mg (equivalent: ondansetron, qty 4 mg) - injection, solution - excipient ingredients: water for injections; sodium hydroxide; citric acid monohydrate; sodium citrate dihydrate; hydrochloric acid; sodium chloride - ondansetron injection is indicated ? for the prevention and treatment of nausea and vomiting induced by cytotoxic therapy and radiotherapy. ? for the prevention and treatment of post-operative nausea and vomiting.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).